Latest news with #IndianPharmaceuticalMarket
Business Upturn
12-08-2025
- Business
- Business Upturn
Alkem Laboratories Q1 Results: Revenue jumps 11.2% YoY to Rs 3,371 crore, net profit up Rs 21.45% YoY
By Aman Shukla Published on August 12, 2025, 13:40 IST Alkem Laboratories has delivered a strong set of numbers for the first quarter of FY26, with growth across revenue, profit, and operational performance. The company reported a consolidated net profit of ₹668 crore, marking a solid 21.45% year-on-year jump from ₹550 crore in the same quarter last year. Revenue also saw healthy growth, rising 11.2% to ₹3,371 crore compared to ₹3,031.8 crore a year ago. The pharmaceutical major's EBITDA stood at ₹739 crore, up 21.35% from ₹609 crore, with margins improving to 21.9% from 20% in the previous year. The domestic business remained the key growth driver, clocking sales of ₹2,265 crore, a 12% increase from the previous year, contributing 68.3% to total sales. According to IQVIA (SSA) data, the company outperformed the Indian Pharmaceutical Market (IPM) in seven therapies, including Gastrointestinal, Vitamins/Minerals/Nutrients, Pain Management, Anti-Diabetics, Neuro/CNS, Respiratory, and Dermatology, with growth ranging from 1.1x to 2.3x the market rate. On the international front, sales stood at ₹1,053.9 crore, registering an 8.9% year-on-year rise. The US business contributed ₹698.2 crore, up 8.8% from last year and accounting for 21% of total sales. Non-US international markets generated ₹355.6 crore, up 9.1%, contributing 10.7% to total revenue. In the US market, Alkem filed its first Biologics License Application (BLA), received five ANDA approvals (including two tentative), and launched three new products during the quarter. As of June 30, 2025, the company had filed 185 ANDAs, two NDAs, and one BLA with the USFDA, receiving approvals for 160 ANDAs (including 15 tentative) and both NDAs. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
12-08-2025
- Business
- Business Upturn
Alkem Laboratories shares jump 6% on strong Q1 results
Alkem Laboratories' stock jumped over 6% after the pharma major delivered an impressive set of numbers for the quarter ended June 30, 2025, driven by robust domestic and international performance. As of 1:46 PM, the shares were trading 6.04% higher at Rs 5,137.00. The company's consolidated net profit rose 21.45% year-on-year to ₹668 crore, compared to ₹550 crore in the same period last year. Revenue climbed 11.2% to ₹3,371 crore from ₹3,031.8 crore, while EBITDA grew 21.35% to ₹739 crore, up from ₹609 crore a year ago. Margins also improved to 21.9%, against 20% in the previous year, reflecting operational efficiency. Domestic market The domestic formulations business remained Alkem's biggest revenue contributor, generating ₹2,265 crore in sales — a 12% YoY increase and accounting for 68.3% of the company's total revenue. As per IQVIA (SSA) data, Alkem outperformed the Indian Pharmaceutical Market (IPM) in seven key therapies — Gastrointestinal, Vitamins/Minerals/Nutrients, Pain Management, Anti-Diabetics, Neuro/CNS, Respiratory, and Dermatology — growing at 1.1x to 2.3x the market rate. International market International sales rose 8.9% YoY to ₹1,053.9 crore. The US business, which contributes 21% to total sales, clocked ₹698.2 crore, up 8.8% from last year. Non-US international markets brought in ₹355.6 crore, marking a 9.1% increase and contributing 10.7% to total revenue. In the US market, Alkem made significant strides, including filing its first Biologics License Application (BLA), securing five Abbreviated New Drug Application (ANDA) approvals (two tentative), and launching three new products during the quarter. As of June 30, 2025, the company had filed 185 ANDAs, two New Drug Applications (NDAs), and one BLA with the USFDA, with approvals for 160 ANDAs (including 15 tentative) and both NDAs. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash
Yahoo
30-06-2025
- Business
- Yahoo
Torrent Pharmaceuticals to acquire stake in JB Pharma for $3bn
Torrent Pharmaceuticals, headquartered in Gujerat, India, has signed definitive agreements for the acquisition of a controlling stake in JB Chemicals and Pharmaceuticals (JB Pharma) from global investment firm KKR at an equity valuation of Rs256.89bn ($3bn) on a fully diluted basis. The move is part of Torrent's strategy to create a diversified healthcare platform that combines its chronic segment expertise with growing international contract development and manufacturing organisation capabilities. The acquisition will take place in two stages. Initially, Torrent will purchase a 46.39% equity stake through a share purchase agreement at a price of Rs119.17bn. This will be followed by a mandatory open offer to public shareholders to acquire up to 26% of JB Pharma shares at Rs1,639.18 per share. Torrent intends to buy up to 2.8% of equity shares from JB Pharma employees at the same price per share as offered to KKR. Following the acquisition, a merger between Torrent and JB Pharma will be executed through a scheme of arrangement. Shareholders of JB Pharma will receive 51 shares of Torrent for every 100 shares held post-merger, as approved by the boards of directors of both companies. The acquisition will provide Torrent with access to a fast-growing Indian franchise, major chronic segment brands and new therapeutic areas such as ophthalmology. It will also strengthen Torrent's market share in the Indian pharmaceutical market (IPM) and offer operational synergies across business functions. JB Pharma CEO and whole time director Nikhil Chopra stated: 'As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organisations will unlock greater opportunities to enhance healthcare access across our markets.' The share purchase agreement and the merger scheme are subject to standard statutory and regulatory approvals, including from the Stock Exchanges, Securities and Exchange Board of India, the Competition Commission of India, the National Company Law Tribunal and other relevant authorities. Moelis & Company and NovaOne served as financial advisors, and Khaitan & Co as legal counsel to Torrent. Ernst and Young Merchant Banking Services and BDO Valuation Advisory acted as independent valuers for Torrent and JB Pharma respectively. KKR's financial advisors were Kotak Investment Banking and Rothschild & Co. Shardul Amarchand Mangaldas & Co provided legal counsel to JB Pharma and KKR. Goldman Sachs (India) Securities and AZB & Partners advised JB Pharma on financial and legal matters respectively. "Torrent Pharmaceuticals to acquire stake in JB Pharma for $3bn" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Mint
05-06-2025
- Business
- Mint
Stocks to buy: Lupin, Aurobindo, Max Healthcare among Axis Sec's top pharma & hospital picks post strong Q4
Stocks to buy: Axis Securities has reaffirmed its bullish view on the pharmaceuticals and hospital sectors in its latest report following the March quarter results, reiterating confidence in select stocks such as Lupin, Aurobindo Pharma, Max Healthcare, and Fortis Healthcare, citing emerging opportunities supported by strong fundamentals and favorable industry dynamics. The brokerage noted that the pharmaceuticals industry appears well-positioned for FY26 and beyond, supported by a strong product pipeline in biosimilars, GLP-1, and peptides. It highlighted that chronic therapies continue to outperform the overall Indian Pharmaceutical Market (IPM), contributing to sustained growth. Additionally, margins are expected to remain stable to improving, aided by a favorable product mix and easing input costs. The US generics business also shows continued strength, with leading players like Lupin and Aurobindo Pharma maintaining meaningful market shares despite ongoing competitive pressures and anticipated low single-digit price erosion. Stock Name Rating Latest closing price Target price Upside Potential Aurobindo Pharma Buy ₹ 1,138 ₹ 1,500 31.2% Lupin Buy ₹ 1,944 ₹ 2,500 28.6% Max Healthcare Institute Buy ₹ 1,147 ₹ 1315 15% Fortis Healthcare Buy ₹ 729 ₹ 775 6.3% Axis believes that companies with a differentiated portfolio and greater exposure to complex generics are likely to outperform in this environment. Consequently, it maintained 'buy' on Aurobindo Pharma and Lupin with a 'buy' rating and has a target price of ₹ 1,500 and ₹ 2500, respectively. In the hospital space, Axis Securities observed that the growth trajectory remains strong, backed by structural tailwinds. These include increased surgical volumes, an improved payer mix, and rising demand for high-growth therapies such as cancer and cardiac care—all of which are contributing to higher ARPOB (average revenue per occupied bed) and occupancy rates. The brokerage expects industry ARPOB to grow at 6–7% annually, with a 100-basis-point improvement in occupancy rates, supporting further margin expansion. Max Healthcare and Fortis Healthcare are viewed as well-positioned to benefit from these secular growth trends, given their scalable operations and strong execution across key metrics. Therefore, it retained a 'buy' recommendation on both the stocks, with a price target of ₹ 1,315 on Max Healthcare shares and ₹ 775 apiece on Fortis Healthcare shares. The pharmaceutical sector delivered a healthy performance in Q4FY25, with revenue growth of 12.3% YoY and 2.3% QoQ, driven primarily by the India business (11.2% YoY). The US generics business recorded 7.7% YoY growth in CC terms, aided by the launch of niche products and price stability. Improvement in gross margins to 66.1% (up 95 bps YoY) was underpinned by a favourable mix shift, muted price erosion, and stable input costs, said Axis Securities. In the hospital sector, revenue grew by 20% YoY and 2% QoQ, supported by higher occupancy rates (+60 bps YoY), an ARPOB increase of 6% YoY, and an 18% rise in operational bed days. Notably, the brokerage stated that the contribution of insurance payers rose to 33%, indicating deeper penetration and improved affordability. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before taking any investment decisions.
&w=3840&q=100)
Business Standard
14-05-2025
- Business
- Business Standard
JB Pharma Q4 results: Profit up 15% to ₹145.6 cr; revenue rises 10%
JB Chemicals and Pharmaceuticals reported a 15 per cent year-on-year (Y-o-Y) increase in net profit for Q4 FY25, reaching ₹145.6 crore, while revenue from operations rose 10 per cent Y-o-Y to ₹949.4 crore. Sequentially, net profit declined 10.3 per cent, while revenue fell 1.4 per cent. For the full financial year (FY25), consolidated net profit rose 19.3 per cent to ₹659.5 crore, and revenue from operations increased 12.4 per cent to ₹3,918 crore. Nikhil Chopra, CEO and wholetime director of JB Pharma, said: 'We have closed the financial year FY25 on a strong note, in line with our strategic intent. Our domestic business continues to be one of the fastest growing in the Indian Pharmaceutical Market (IPM). With 75 per cent of India branded formulations sales in progressive, faster-growing segments, we are confident in sustained strong performance going forward.' The stock rose 1.94 per cent to ₹1,610.50 apiece on the BSE. The results were announced after market hours on Wednesday. In Q4, the company's domestic business registered 11 per cent Y-o-Y growth to ₹519 crore. According to IQVIA data, JB Pharma grew 13 per cent Y-o-Y in the quarter, nearly double the Indian Pharmaceutical Market (IPM) growth of 7 per cent. Excluding its ophthalmology portfolio, JB Pharma's growth stood at 12 per cent. Prescription volumes rose 7 per cent Y-o-Y during the quarter. The chronic portfolio recorded strong growth of 16 per cent, while the acute segment grew 10 per cent, as per IQVIA. The ophthalmology segment was a standout performer, growing 22 per cent Y-o-Y to ₹56 crore, compared to ₹46 crore a year earlier. The international business delivered revenue of ₹430 crore in Q4 FY25, up 9 per cent Y-o-Y. Within this, the international formulations business rose 6 per cent to ₹282 crore, driven by double-digit growth in markets like Russia and in the branded generics export segment. JB Pharma's contract development and manufacturing (CDMO) business posted 18 per cent growth during the quarter, with revenue of ₹129 crore and a robust order book for the coming quarters. However, the active pharmaceutical ingredient (API) business remained muted, contributing ₹19 crore in sales. The combined share of the domestic and CDMO businesses increased to 69 per cent of overall revenue, up from 55 per cent in FY21. The domestic business grew 20 per cent annually to ₹2,269 crore, led by sustained demand across therapeutic areas. Excluding ophthalmology, the domestic portfolio registered 13 per cent growth. JB Pharma's international business rose 4 per cent to ₹1,649 crore in FY25, with Russia and branded generics exports recording healthy double-digit growth. The CDMO segment also delivered strong performance in the second half of the fiscal.
